Information Provided By: 
Fly News Breaks for February 25, 2020
MEDP
Feb 25, 2020 | 07:45 EDT
Credit Suisse analyst Erin Wilson Wright raised her price target for Medpace to $99 from $91 following quarterly results and to reflect a higher view and greater conviction in its growth prospects in a strong fundamental backdrop. The analyst reiterates an Outperform rating on the stock, adding that momentum in the shares may continue on the latest Q4 and 2020 operational guidance upside.
News For MEDP From the Last 2 Days
MEDP
Apr 24, 2024 | 07:15 EDT
Guggenheim raised the firm's price target on Medpace to $464 from $453 and keeps a Buy rating on the shares after an EBITDA and EPS beat-and-raise was supported by "generally positive commentary" on the call. Demand remains strong and Medpace has found ways to be more efficient, meeting its demand needs with lower headcount growth, adds the analyst, who notes that management continues to expect the current environment to support accelerating revenue growth in 2025.
